Publicacións en colaboración con investigadores/as de Hospital Universitario de Salamanca (20)

2024

  1. MiRNome Profiling of Extracellular Vesicles in Patients with Severe COVID-19 and Identification of Predictors of Mortality

    Journal of Infectious Diseases, Vol. 230, Núm. 4, pp. 901-911

  2. Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA

    Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 11, pp. 2280-2290

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91

  3. Incidence, and natural history of inflammatory bowel disease in Castilla y León: Prospective and multicenter epidemiological study

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 2, pp. 102-108

2022

  1. Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)

    Journal of Clinical Medicine

  2. Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients

    Frontiers in Medicine, Vol. 9

  3. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

2021

  1. Can the Cytokine Profile According to ABO Blood Groups Be Related to Worse Outcome in COVID-19 Patients? Yes, They Can

    Frontiers in Immunology, Vol. 12

  2. Evaluation of cytokines as robust diagnostic biomarkers for COVID-19 detection

    Journal of Personalized Medicine, Vol. 11, Núm. 7

  3. HGF, IL-1α, and IL-27 are robust biomarkers in early severity stratification of COVID-19 patients

    Journal of Clinical Medicine, Vol. 10, Núm. 9

  4. Incidence, clinical characteristics and management of inflammatory bowel disease in spain: Large-scale epidemiological study

    Journal of Clinical Medicine, Vol. 10, Núm. 13

2020

  1. Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients with Inflammatory Bowel Disease: Results from the Eneida Registry

    Inflammatory Bowel Diseases, Vol. 26, Núm. 4, pp. 606-616

2019

  1. Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results from the ENEIDA Registry

    Inflammatory Bowel Diseases, Vol. 25, Núm. 11, pp. 1862-1870

  2. Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study

    Journal of Crohn's & colitis, Vol. 13, Núm. 12, pp. 1492-1500

2018

  1. Formin Homology 2 Domain Containing 3 (FHOD3) Is a Genetic Basis for Hypertrophic Cardiomyopathy

    Journal of the American College of Cardiology, Vol. 72, Núm. 20, pp. 2457-2467

2017

  1. Evolution after Anti-TNF Discontinuation in Patients with Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study

    American Journal of Gastroenterology, Vol. 112, Núm. 1, pp. 120-131

2016

  1. Incidence, clinical characteristics, and management of psoriasis induced by Anti-TNF therapy in patients with inflammatory bowel disease: A nationwide cohort study

    Inflammatory Bowel Diseases, Vol. 22, Núm. 4, pp. 894-901

2014

  1. Diagnosis and allergen immunotherapy treatment of polysensitised patients with respiratory allergy in Spain: An Allergists' Consensus

    Clinical and Translational Allergy, Vol. 4, Núm. 1

2006

  1. Epidemiología de la diabetes tipo 1 en menores de 15 años en las provincias de Castilla y León

    Anales de Pediatria, Vol. 65, Núm. 1, pp. 15-21